Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 17/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828722 | 0.86 | IDH1 (0.38) | P2RX7PDE4AKIF11 | |
| SCHEMBL828723 | 0.81 | P2RX7 (0.40) | P2RX7 | |
| SCHEMBL828523 | 0.81 | P2RX7 (0.39) | P2RX7 | |
| SCHEMBL829082 | 0.80 | IDH1 (0.36) | P2RX7PDE4AKIF11 | |
| SCHEMBL828676 | 0.76 | CYP11B1 (0.40) | P2RX7 | |
| SCHEMBL828703 | 0.68 | CNR2 (0.34) | P2RX7 | |
| SCHEMBL829120 | 0.68 | NPY5R (0.34) | P2RX7 | |
| SCHEMBL829005 | 0.64 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL829240 | 0.64 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL828464 | 0.64 | P2RX7 (0.45) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271640-B1 | Piperidine derivatives as CGRP receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2271640-B1 | Piperidine derivatives as CGRP receptor antagonists | BRISTOL MYERS SQUIBB CO (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143403-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-20120010402-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2012-01-12 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044043-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2271640-A2 | PIPERIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009126530-A2 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126530-A2 | CGRP RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
| US-20090258866-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010402-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | P2RX7 182/4885PDE4A 698/4885KIF11 2946/4885 |
| US-20090258866-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | P2RX7 182/4885PDE4A 698/4885KIF11 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.